#1 Clinical Trials Search in Europe

Mva-209-Fsp-B4

In recent clinical trials, researchers are investigating the potential of Mva-209-Fsp-B4, a component of the Nous-209 genetic vaccine, for treating advanced microsatellite instability-high (MSI-H) colorectal cancer. This innovative approach combines genetic vaccination with immunotherapy, aiming to provide new hope for patients with this challenging form of cancer. The trials are designed to assess the safety, efficacy, and anti-tumor activity of this treatment strategy in various patient populations.

Table of Contents

What is MVA-209-FSP?

MVA-209-FSP is an experimental genetic vaccine being studied for the treatment of certain types of cancer[1]. It is part of a class of treatments called immunotherapies, which work by helping your body’s immune system fight cancer. The full name of this treatment is “Modified Vaccinia Ankara (MVA) 209 Frame Shift Peptide vaccine.”

How does it work?

MVA-209-FSP is composed of four different vectors (carriers) named MVA-209-FSP-B1, MVA-209-FSP-B2, MVA-209-FSP-B3, and MVA-209-FSP-B4[1]. Each of these carriers contains genetic instructions for making 209 special proteins called Frame Shift Peptides (FSPs). These FSPs are abnormal proteins that are often found in certain types of cancer cells but not in normal cells. By introducing these FSPs into the body, the vaccine aims to “train” the immune system to recognize and attack cancer cells that produce these abnormal proteins.

What conditions does it target?

MVA-209-FSP is being studied for the treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer that is locally advanced, unresectable (cannot be removed by surgery), or has spread to other parts of the body (metastatic)[1]. These terms describe specific genetic characteristics of the cancer that make it potentially responsive to this type of treatment.

Current Clinical Trial

MVA-209-FSP is currently being tested in a Phase I/II clinical trial[1]. This means it’s still in the early stages of research. The study is designed to:

  1. Determine if the treatment is safe
  2. See how well it works in fighting cancer
  3. Find the right dose to use
  4. Understand how it interacts with other cancer treatments, particularly a drug called pembrolizumab (another type of immunotherapy)

How is it administered?

MVA-209-FSP is given as an intramuscular injection, which means it’s injected directly into a muscle[1]. The exact schedule of when and how often it’s given will depend on the specific phase of the clinical trial.

Who is eligible for the treatment?

The current clinical trial has specific eligibility criteria. In general, patients must:

  • Be 18 years or older
  • Have confirmed MSI-H or dMMR colorectal cancer
  • Have cancer that is advanced or has spread
  • Be in relatively good overall health
  • Not have certain other medical conditions or be taking certain medications that might interfere with the treatment
It’s important to note that eligibility can vary depending on which part of the trial a patient might enter[1].

Potential Benefits

While it’s too early to know for certain how effective MVA-209-FSP will be, the hope is that it will help the immune system fight cancer more effectively. The researchers are looking at several ways to measure its effectiveness, including:

  • Whether tumors shrink or disappear (called “response rate”)
  • How long any improvements last
  • How long patients live without their cancer getting worse
These potential benefits are still being studied and are not guaranteed[1].

Safety Considerations

As with any experimental treatment, there may be risks and side effects that are not yet fully known. The clinical trial is designed to carefully monitor patients for any adverse effects. Some general considerations include:

  • Patients should not receive certain live vaccines while on this treatment
  • The treatment may affect the immune system, so patients with certain immune-related conditions may not be eligible
  • Pregnant or breastfeeding women are not eligible for the current trial
Always discuss potential risks and benefits with a healthcare provider[1].

Aspect Details
Drug Name Mva-209-Fsp-B4 (part of Nous-209 genetic vaccine)
Trial Phase Phase I/II
Target Condition Advanced MSI-H or dMMR Colorectal Cancer
Administration Intramuscular injection
Combination Therapy Used with pembrolizumab (immunotherapy)
Primary Objectives Assess safety, tolerability, and anti-tumor activity
Key Outcomes Measured Overall Response Rate (ORR), Duration of Response (DoR), Progression-Free Survival (PFS)
Eligibility Adults (18+) with MSI-H/dMMR CRC, meeting specific health criteria

FAQ

  • What is Mva-209-Fsp-B4 and how does it work? Mva-209-Fsp-B4 is one of four vectors in the MVA-209-FSP genetic vaccine. It uses a Modified Vaccinia Ankara (MVA) virus to deliver genetic material encoding Frame Shift Proteins (FSPs). This approach aims to stimulate the immune system to recognize and attack cancer cells with specific genetic mutations.
  • What type of cancer is being targeted in these clinical trials? The trials are focusing on patients with locally advanced unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).
  • How is Mva-209-Fsp-B4 administered to patients? Mva-209-Fsp-B4 is administered as part of the MVA-209-FSP vaccine, which is given as an intramuscular injection. It is used in combination with pembrolizumab, an immunotherapy drug.
  • What are the main objectives of the clinical trials? The main objectives include assessing the safety and tolerability of the treatment, evaluating its anti-tumor activity, and measuring outcomes such as overall response rate (ORR), duration of response (DoR), and progression-free survival (PFS).
  • Who is eligible to participate in these clinical trials? Eligibility criteria include being 18 years or older, having MSI-H or dMMR colorectal cancer, adequate organ function, and meeting specific health requirements. Some trials are for first-line treatment, while others are for patients who have progressed after previous treatments.

Ongoing Clinical Trials on Mva-209-Fsp-B4

  • Study of Nous-209 Genetic Vaccine and Pembrolizumab for Patients with Advanced Microsatellite Instability-High Colorectal Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Italy Spain

Glossary

  • Microsatellite Instability-High (MSI-H): A condition where cells have a high number of genetic mutations in microsatellites, which are short, repeated sequences of DNA. This is often associated with certain types of cancer, including some colorectal cancers.
  • Mismatch Repair Deficient (dMMR): A condition where cells lack the ability to correct mistakes in DNA replication, leading to an accumulation of genetic mutations. This is closely related to MSI-H status.
  • Frame Shift Proteins (FSPs): Proteins produced as a result of genetic mutations that alter the reading frame of DNA, often leading to the production of abnormal proteins that can be recognized by the immune system.
  • Modified Vaccinia Ankara (MVA): A weakened form of the vaccinia virus used as a vector to deliver genetic material in vaccines. It's designed to be safe while effectively stimulating an immune response.
  • Overall Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Duration of Response (DoR): The length of time that a tumor continues to respond to treatment without growing or spreading.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • RECIST v1.1: Response Evaluation Criteria in Solid Tumors version 1.1, a standardized method to measure how well a cancer patient responds to treatment.

References

  1. http://clinicaltrials.eu/trial/study-of-nous-209-genetic-vaccine-and-pembrolizumab-for-patients-with-advanced-microsatellite-instability-high-colorectal-cancer/